Abstract P4-02-13: Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trialsGaia Griguolo, Maria Vittoria Dieci, Simon Spazzapan et al.|Cancer Research|2023Cited by 2
Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials.Gaia Griguolo, Valentina Guarneri, Laia Paré et al.|Journal of Clinical Oncology|2024Cited by 1
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implicationsGaia Griguolo, Valentina Guarneri, Michele Bottosso et al.|npj Breast Cancer|2025Cited by 1